Extended release ropivacaine hydrochloride - Cali Pharmaceuticals
Alternative Names: CPL-01Latest Information Update: 13 Jun 2023
Price :
$50 *
At a glance
- Originator Cali Pharmaceuticals
- Class Analgesics; Anilides; Local anaesthetics; Non-opioid analgesics; Piperidines; Small molecules
- Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Postoperative pain
Most Recent Events
- 13 Jun 2023 Cali Pharmaceuticals initiates a phase III trial for Post operative pain (In adults, In the elderly) in USA (Injection) (NCT05831449)
- 02 May 2023 Cali Pharmaceuticals plans a phase III trial for Post operative pain (In adults, In the elderly) in USA (Injection) (NCT05831449)
- 07 Apr 2023 Phase-III clinical trials in Postoperative pain (In adults, In elderly) in USA (Injection) (NCT05813847)